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Protocol
AbstrAct
Introduction Interventions using robot-assisted therapy 
may be beneficial for the social skills development of 
children with autism spectrum disorder (ASD); however, 
randomised controlled trials (RCTs) are lacking. The 
present research aims to assess the feasibility of 
conducting an RCT evaluating the effectiveness of a social 
skills intervention using Kinesics and Synchronisation in 
Personal Assistant Robotics (Kaspar) with children with 
ASD.
Methods and analysis Forty children will be recruited. 
Inclusion criteria are the following: aged 5–10 years, 
confirmed ASD diagnosis, IQ over 70, English-language 
comprehension, a carer who can complete questionnaires 
in English and no current participation in a private social 
communication intervention. Children will be randomised 
to receive an intervention with a therapist and Kaspar, or 
with the therapist only. They will receive two familiarisation 
sessions and six treatment sessions for 8 weeks. They 
will be assessed at baseline, and at 10 and 22 weeks after 
baseline. The primary outcome of this study is to evaluate 
whether the predetermined feasibility criteria for a full-scale 
trial are met. The potential primary outcome measures for a 
full-scale trial are the Social Communication Questionnaire 
and the Social Skills Improvement System. We will conduct 
a preliminary economic analysis. After the study has ended, 
a sample of 20 participants and their families will be invited 
to participate in semistructured interviews to explore the 
feasibility and acceptability of the study’s methods and 
intervention.
Ethics and dissemination Parents/carers will provide 
informed consent, and children will give assent, where 
appropriate. Care will be taken to avoid pressure or 
coercion to participate. Aftercare is available from the 
recruiting NHS Trust, and a phased withdrawal protocol 
will be followed if children become excessively attached 
to the robot. The results of the study will be disseminated 
to academic audiences and non-academic stakeholders, 
for example, families of children with ASD, support groups, 
clinicians and charities.
Trial registration number ISRCTN registry 
(ISRCTN14156001); Pre-results.
InTroducTIon
Autism spectrum disorder (ASD) is a lifelong, 
neurodevelopmental condition that affects 
approximately 1 in 100 individuals in the 
UK.1 According to the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition, a diag-
nosis of ASD requires deficits to be present 
in social communication and interaction and 
restricted, repetitive patterns of behaviour, 
interests or activities.2 Given the profile of 
difficulties associated with ASD, individuals 
may experience challenges with independent 
living, self-care, developing meaningful rela-
tionships and educational and employment 
prospects.3 4 Furthermore, ASD does not just 
affect the health of the individual; parenting 
a child with ASD is a strong factor in parental 
anxiety and depression.5 6
Any intervention should focus on devel-
oping children’s social skills as it has been 
shown that social competence is a predictor 
Strengths and limitations of this study
 ► This study will be the first randomised controlled 
trial of a robot-assisted social skills intervention for 
children with autism spectrum disorder.
 ► The study design, management and data analysis 
benefit from the input of experts by experience.
 ► Quantitative, qualitative and economic analyses will 
provide a comprehensive picture of feasibility.
 ► A definitive trial would be necessary to evaluate the 
effectiveness of the intervention.
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of long-term outcomes for individuals with ASD.7 Further-
more, it is well established that early intervention yields 
best outcomes,4 8 9 so an intervention delivered soon after 
diagnosis affords the child the best opportunity to develop 
the basic skills required to fuel social competence.
The National Institute for Health and Care Excel-
lence (NICE) guidelines indicate that children should 
be offered psychosocial intervention as a first-line treat-
ment.10 One specific avenue of research has explored the 
use of such an intervention using social robots to support 
the social and emotional development of children with 
ASD. Robots have been shown to be effective social 
mediators, encouraging and facilitating social behaviour 
between children with ASD and developing their social 
skills.11–14
Kinesics and Synchronisation in Personal Assistant 
Robotics (Kaspar) is a minimally expressive humanoid 
robot. People’s social behaviour can be very subtle and can 
appear widely unpredictable to a child with ASD. Kaspar’s 
face has been depersonalised by reducing the detail so 
that the facial features are easily recognisable,15 therefore 
aiming to help children with ASD to identify and under-
stand facial expressions and social interactions.16
Psychosocial interventions for ASD should include play-
based strategies to increase joint attention, engagement 
and reciprocal communication.10 The games or scenarios 
that children can play with Kaspar have been designed so 
that they each contain elements of joint attention, imita-
tion, turn-taking, cause and effect and collaboration. 
Evidence from case studies has shown promising results 
from using Kaspar with children with ASD. Teachers have 
reported improvements in children’s behaviour.17 Collab-
orative and play skills among children with ASD have 
shown improvement following sessions with Kaspar and 
another child,16 and carers are positive about the effects 
of the intervention on their child.15
The use of robot-assisted therapy with children with 
ASD is a rapidly growing area.18–22 However, although 
previous research suggests numerous educational and 
therapeutic benefits for children, much of what is known 
about the use of robots in interventions has been gleaned 
from single case reports. Virtually all peer-reviewed 
studies in this field have been preliminary and explor-
atory,21 but research demonstrating the effectiveness of 
social skills interventions should use rigorous research 
designs.23 As such, there is a need for studies to use group 
research designs, especially true experimental designs 
such as randomised controlled trials (RCTs) in order to 
unearth the usefulness of robot-mediated interaction for 
children with ASD.
Aims and objectives
The present research aims to conduct a feasibility study of 
an RCT exploring the effectiveness of a humanoid robot 
to support social skills development in children with 
ASD. This feasibility study has a single-blind, randomised 
design, which will compare the Kaspar group (KG) to a 
group who have the same interaction with a therapist only 
(TOG), thereby exploring any specific effects of using a 
robot to facilitate the delivery of a social skills interven-
tion. This article reports the protocol (v3.0, 24 February 
2017) for the ‘Kaspar RCT’ study and follows SPIRIT 
(Standard Protocol Items: Recommendations for Inter-
ventional Trials) reporting guidelines.24
The study objectives are to assess the feasibility and 
acceptability of:
1. recruiting children with ASD to a randomised study 
and exploring rates of attrition
2. data collection for the outcome measures
3. estimating cost-effectiveness in a definitive trial
4. integrating a social skills intervention within the 
routine activity of an NHS Trust’s ASD diagnostic 
clinic
5. the study’s procedures and intervention among 
parents and children with ASD.
The following criteria will have to be met, or robust 
evidence will have to be presented to amend the study 
design, to proceed to a full-scale RCT:
1. More than 40% recruitment rate;
2. Less than 35% attrition;
3. Completion of at least 80% of the questionnaires;
4. Any issues with study design identified in the feasibility 
study can be addressed;
5. Good acceptability of the intervention among patients 
and their families as indicated in qualitative feedback;
6. Positive feedback from clinical staff about scheduling 
clinics;
7. The 80% CI of the effect size between the groups on 
a potential primary outcome measure excludes zero.
MeThods And AnAlysIs
design and setting
A single-blind feasibility RCT with two parallel groups 
based at a single NHS Trust in England (Hertfordshire 
Community NHS Trust) will be conducted for 24 months. 
Children will be randomised to receive an intervention 
with Kaspar and a therapist (KG), or the same interven-
tion but with a TOG.
This study is a mixed design with between-group and 
within-participant comparisons to explore the feasibility 
of delivering a large-scale RCT.
Participants
Forty children will be recruited through clinics in Hert-
fordshire Community NHS Trust that provide assessment 
and support to children with ASD, for example, the 
Communication Disorders Assessment Clinic (CDAC) 
in Watford to which approximately 1000 children a year 
are referred for a potential ASD diagnosis. The clinical 
team will screen children from their existing records and 
identify eligible children. Children who have been diag-
nosed in the last 12 months will be identified in the first 
instance with this time period being extended if necessary 
for recruitment.
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Inclusion/exclusion criteria
Inclusion criteria
 ► Aged 5–10 years;
 ► Diagnosis of an ASD confirmed with the Autism 
Diagnostic Observation Schedule25 and/or the 
Autism Diagnostic Interview26 within the last 12 
months;
 ► Able to understand or fluently speak English;
 ► IQ >70.
Exclusion criteria
 ► Currently in receipt of a privately delivered social 
communication intervention (ie, not part of NHS or 
education usual care);
 ► The child is non-English speaking or if non-verbal, 
unable to understand English;
 ► Carer who is completing the questionnaire is unable 
to do so in English.
recruitment procedure
Figure 1 shows the flow of participants through the study. 
Parents/carers of children meeting the inclusion criteria 
will be given details of the study at a routine clinic appoint-
ment or over the phone by a member of the clinical team, 
and they will be invited to complete a consent form to refer 
them to the research team for further information about 
the study. They will also have the opportunity to complete 
an ‘opt-out’ form if they would prefer not to be contacted 
again about the study. Information sheets designed for 
parents and children will be used. For all screened chil-
dren, the clinical team will note down whether they were 
referred to the research team, if they were not eligible (and 
why) or if they declined (and why, if a reason is given). 
For those children who are referred to the research team, 
the parent/carer will be contacted approximately 2 weeks 
later and will be invited to a meeting with a member of the 
research team. This will be at a mutually convenient time 
and place, for example, the family’s home, the clinic or the 
University of Hertfordshire. A researcher will explain the 
project using the parent and child information sheets, and 
if the parent/carer would like to take part, then they will 
take consent from the parent/carer and assent from the 
child, where appropriate. Parents/carers who consent to 
study participation will also be asked if they consent to be 
recontacted at a later stage about participating in a semi-
structured interview.
The researcher will carry out an IQ test with the 
child to ensure that they meet the eligibility criteria of 
an IQ of at least 70. The Universal Non-verbal Intelli-
gence Test27 will be used as it has completely non-verbal 
instructions and is for use with children between 5 and 
21 years.
All members of the clinical and research team involved 
in recruitment will be trained in good clinical practice 
(GCP). The child’s GP and school will be informed about 
the study, if the parent/carer consents to this.
Randomisation
After the initial visit from the research team, the child 
will be randomised to either the KG or TOG. Individual 
randomisation will be performed on the online study 
database on Qualtrics by the trial coordinator, and the 
outcome will be shared with the therapist.
Families will be contacted when appointments for 
the intervention sessions are available. Parents/carers 
will not be informed which group their child has been 
randomised to at this point. They will be informed after 
the baseline assessment has been conducted (ie, before 
the intervention begins) to ensure that any disappoint-
ment at group allocation does not affect the baseline 
completion of the study questionnaires.
The trial coordinator, therapist and participants are 
unable to be blinded, but the research assistant who 
will collect data at T0 (baseline), T1 (10 weeks postbase-
line) and T2 (22 weeks postbaseline) will be blinded. In 
order to maximise the chance that the research assistant 
remains blind to allocation, parents/carers will be asked 
not to share with the research assistant which group they 
have been allocated to. Any breach in blinding will be 
reported to the trial steering group (TSG) and will inform 
the design of a definitive RCT.
Kaspar and therapist-only interventions
At the start of the intervention period, each child will 
receive two 15 min sessions with Kaspar and the therapist 
(KG) or with the therapist (TOG), depending on their 
group allocation. The purpose of these sessions will be to 
familiarise the children with Kaspar and/or the therapist. 
The intervention itself will consist of six weekly sessions 
with Kaspar and the therapist (KG), or with the thera-
pist (TOG). KG children will be encouraged to interact 
with the therapist in order to play with Kaspar. The inter-
actions will last for up to 20 min. A research nurse will act 
as the therapist and will receive full training in the social 
skills intervention and how to use Kaspar.
The weekly intervention sessions will involve the child 
playing a series of games with the therapist and/or 
Kaspar. The same games will be played in both groups, 
but the KG will play these games with the therapist and 
Kaspar and the TOG will play these games with the ther-
apist. The games to be played have been designed so 
that they contain elements of joint attention, imitation, 
turn-taking, cause and effect and collaboration, and the 
therapist can select games based on the child’s responses 
in the session. It is important that any intervention to 
be used with children with ASD can be adapted for the 
individual child, as each child’s interests, preferences and 
capabilities may vary significantly.20
The interventions will be run as would normally be 
done in an ASD diagnostic clinic. Therefore, a list of 
participants for each group will be kept until a minimum 
number of participants (approximately six) have accrued 
for the therapist to run clinic sessions. Parents/carers will 
then be contacted and informed of available dates. Both 
interventions will be delivered in a clinic in Hertfordshire 
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Community NHS Trust with a one-way mirror, which will 
allow parents to observe the intervention. The interven-
tion sessions will also be video-recorded (depending on 
parental consent) so that the therapist can review the 
sessions and observations can be coded. The therapist will 
complete an intervention record form for each child’s 
familiarisation and therapy session.
Once their data collection has been completed, each 
child in the TOG will be given the opportunity to receive 
the intervention in the same way as the KG.
Assessments
Each participant will be assessed through screening 
measures and three questionnaires at baseline, 10 weeks 
later and 22 weeks later in face-to-face research visits with 
a trained research assistant at a convenient location for the 
families (eg, their home/the clinic/the university). Obser-
vational data will also be collected during the intervention. 
A subgroup of participants will be invited to take part in 
a semistructured interview in order to glean their perspec-
tives on the intervention and study process.
Figure 1 Study flow chart. Kaspar , Kinesics and Synchronisation in Personal Assistant Robotics.
 5Mengoni SE, et al. BMJ Open 2017;7:e017376. doi:10.1136/bmjopen-2017-017376
Open Access
Baseline and follow-up questionnaires
Shortly before their first clinic appointment, the research 
assistant will contact the parent/carer to arrange the base-
line assessment at a mutually convenient location. This is 
so the parent/carer can ask questions and also to ensure 
that the questionnaires are completed. This meeting will 
take place at a location that is most suitable for the partic-
ipant (their home/clinic/university). After this visit, the 
parent/carer will be informed about which group their 
child has been allocated to by the trial coordinator or 
therapist.
Within 2 weeks of the end of the intervention (approxi-
mately 10 weeks after the baseline assessment), the child’s 
parents/carers will be contacted to arrange a visit to 
complete the questionnaires again.
Three months after the end of the intervention (approx-
imately 22 weeks after the baseline assessment), parents/
carers will again be contacted to arrange the final data 
collection visit.
The questionnaires to be used in the baseline and 
follow-up assessments can be seen in figure 2. The 
measures selected have been widely used in the target 
Figure 2 Study schedule. ADI, Autism Diagnostic Interview; ADOS, Autism Diagnostic Observation Schedule; CA-SUS, Child 
and Adolescent Service Use Schedule; CHU-9D, Child Health Utility 9D; Kaspar, Kinesics and Synchronisation in Personal 
Assistant Robotics; PSI-4-SF, Parenting Stress Index (Fourth Edition, Short Form); SCQ, Social Communication Questionnaire; 
UNIT, Universal Non-verbal Intelligence Test.
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population and are straightforward to complete. The 
potential primary outcome measures for the full-scale trial 
are the Social Communication Questionnaire (SCQ)28 
and the Social Skills Improvement System (SSIS).29 The 
SCQ is a parental questionnaire assessing child behaviour 
associated with ASD, and the SSIS is a parental ques-
tionnaire assessing children’s social skills and problem 
behaviours. The Parenting Stress Index (Fourth Edition, 
Short Form) will likely be a secondary outcome measure 
in the full-scale trial and is a self-report questionnaire with 
three subscales: parental distress, parent–child dysfunc-
tion interaction and difficult child.30
The economic analysis will use the Child Health 
Utility 9D (CHU-9D)31 and an amended version of the 
Child and Adolescent Service Use Schedule (CA-SUS).32 
The CHU-9D is a health-related quality of life question-
naire. The self-report version will be used with the child 
where possible, and the proxy version will be used for 
parental completion where the child is deemed as not 
able to complete the questionnaire. The CA-SUS is a 
parent/carer self-report questionnaire, which will collect 
information about the child’s use of NHS, personal social 
services (PSS) and education costs, as well as parent/
carer costs.
Intervention observations
All intervention sessions will be video-recorded with 
consent from parents. Each participant’s first and final 
intervention session, that is, not the familiarisation 
sessions, will be coded for frequency and duration of 
joint attention and imitation using the observer system. 
To ensure reliability, 20% of the recorded intervention 
sessions will be independently coded by two researchers, 
and Cohen’s kappa will be computed.
Semistructured interviews
Interviews with parents/carers and children will be 
conducted by a trained researcher and with a sample of 
10 participants from each group. Purposeful sampling 
will be used to ensure a diverse range of views are repre-
sented, for example, a range of ages, ability levels and 
dates of entry into the study. When the research assistant 
arranges the 22 -week follow-up, they will also ask if the 
selected parents/carers would be happy to take part in 
an interview, which would occur shortly after the visit 
to complete the questionnaires. Information sheets and 
consent/assent forms will be used to explain the purpose 
of the interviews and what would be involved.
The interviews will take place at a location that is 
most suitable for the participant (their home/clinic/
University) and will be audio-recorded. A semistructured 
interview topic guide will be followed and will address 
the feasibility and acceptability of the recruitment proce-
dures, questionnaire completion and intervention.
Towards the end of the study, health professionals 
will also take part in an audio-recorded semistructured 
interview to explore the feasibility of the trial design and 
intervention. Key staff members will be contacted and 
provided with an information sheet, and if they choose to 
take part, then they will be asked to complete a consent 
form.
study termination
The final questionnaire assessment point will be at week 
22, and for those who are taking part in interviews, these 
will be arranged to take place shortly after the question-
naire completion. After this, children in the KG will 
resume care as usual. Children in the TOG will be offered 
sessions with Kaspar at the end of the study, which will 
follow the same format as the sessions received by the KG.
If a child withdraws from the study at any point, then 
they will be referred to usual care.
data analysis
The data analysis will enable the feasibility criteria to be 
addressed to inform the decision about recommending a 
definitive trial and will explore the following outcomes:
 ► The demographical and clinical characteristics of 
those who take part in the study;
 ► Recruitment rates (per month);
 ► Rate of attrition of participants in each arm of the 
study;
 ► Completion rates of the outcome measures;
 ► The suitability of outcome measures for the definitive 
trial;
 ► The feasibility of collecting resource use and quality 
of life data;
 ► The acceptability of the intervention to clinicians 
and parents;
 ► The practicality of running the clinics where the 
intervention is delivered in the NHS setting.
Data will be entered to the online study database, and 
this will be primarily undertaken by the research assistant, 
with a random 10% of questionnaires being checked by 
another member of the research team.
Stata will be used to conduct the statistical analysis, 
which will seek to evaluate the feasibility of undertaking 
a large-scale trial. The analysis will primarily be descrip-
tive, aimed at estimating the parameters (mean, SD and 
proportions) required to design a definitive trial. Thus, 
the analysis will tabulate the data required to inform the 
decision whether to proceed: number of patients iden-
tified, number and proportion of patients recruited, 
proportion of patients completing the intervention and 
proportion of questionnaires completed.
Regarding potential outcome measures for the main 
study, the observed effect sizes of group differences will 
be observed at the two follow-ups, and the extent to 
which these outcomes indicate an effect size >0 will be 
calculated.33 The analysis will also consider which of the 
potential primary outcomes (SSIS and SCQ) is likely to 
be more sensitive to the intervention. These data will be 
used to inform sample size estimation for a future defini-
tive trial. The findings from the observational coding will 
be reported, and the ease and reliability of this coding 
will inform the design of a full-scale trial.
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Estimation of cost-effectiveness, within a health-tech-
nology assessment, is an iterative process.34 Levels of 
resource use and quality of life will be monitored to 
inform the decision as to how costs and benefits should 
be measured as part of a definitive study. Associated unit 
costs35 will be assigned to all items of NHS, PSS and educa-
tion resource use indicated on the CA-SUS. Responses 
to the CHU-9D can be converted into a utility score (a 
scale where death is equal to 0 and full health 1)31 and, in 
turn, quality-adjusted life year scores.36
Interview data will be analysed using thematic analysis37 
in NVivo, a qualitative data analysis software programme. 
The emerging themes will be discussed with the patient 
and public involvement (PPI) representatives who 
will receive basic training in the methodology run by a 
member of the research team with qualitative expertise.
sample size and feasibility of recruitment
As a feasibility study, the sample size is estimated following 
Cocks and Torgerson.33 The outcome measures intended 
for the definitive trial will be determined by this study, 
and the primary outcome measure will either be the 
SCQ or the SSIS. We estimate the power for this study 
assuming the effect size for the full trial will be at least 
0.3. Assuming α=0.05 and 1−β=0.8, the required sample 
size to be able to reject an effect size of 0 would be n=13 
per arm. Assuming a sample size of n=20 per arm (n=40 
in total) will allow for attrition of 35% in the study.
Children will be recruited through a clinic assessing 
children referred for communication disorders in Hert-
fordshire Community NHS Trust. In the first instance, 
we will work with the CDAC in Watford, as a preliminary 
audit confirmed that 125 participants meeting the inclu-
sion criteria are diagnosed each year. Applying a refusal 
rate of 40% (as gleaned from our broad experience of 
research) would mean that 75 would take part. However, if 
recruitment rates are lower than expected, then children 
who have been diagnosed the previous year will be invited 
to participate and/or we will identify and approach addi-
tional clinics in Hertfordshire Community NHS Trust.
study management
The study started on 1 December 2016 and will finish 
on 30 November 2018. The study is cosponsored by 
Hertfordshire Community NHS Trust (lead sponsor) 
and University of Hertfordshire. The study is funded 
by the National Institute for Health Research (NIHR) 
who plays no role in the study design, conduct, analysis 
or report writing. The study was registered as a clinical 
trial with ISRCTN registry on 23 February 2017, and any 
changes to the protocol will be updated on the registry as 
necessary.
The TSG will comprise the protocol authors along with a 
representative from Hertfordshire Community NHS Trust 
Research and Development Office and the study research 
assistant. The TSG will meet quarterly and be responsible 
for monitoring the progress and conduct of the study, 
addressing key issues that may arise and reporting to 
the funder and the research ethics committee (REC). As 
this is a feasibility study involving low-risk interventions, 
it is considered that a data-monitoring committee is not 
needed. The TSG will have the responsibility to change 
the protocol and/or stop the trial at any point if needed, 
and to notify relevant parties, for example, the sponsors 
and REC.
The project advisory group will include core members 
of the study team and experts by experience. They will 
meet two times per year in person or by telephone confer-
ence. The meetings will be scheduled so that the output 
will inform the TSG meetings.
A core team involved in the day-to-day running of the 
study will form the trial management group to ensure 
all practical aspects of the trial are progressing well and 
to identify potential issues as early as possible. They will 
meet on a monthly basis in person, by telephone confer-
ence or through email discussion, where appropriate.
Adverse events
From previous studies with Kaspar and other psychoso-
cial interventions with children with ASD, the likelihood 
of a (serious) adverse event or reaction occurring is low. 
However, if these are suspected to have occurred, they will 
be recorded. The TSG and sponsors will be notified, and 
their guidance will be followed regarding further notifica-
tion of other parties, for example, the REC.
data management
This study will be conducted in accordance with the Data 
Protection Act (1998) and the guidelines of the Declara-
tion of Helsinki (1964; updated Tokyo, 2004).
Data management will be coordinated from the Univer-
sity of Hertfordshire. Access to patient-identifiable data, 
for example, consent forms, will be restricted to authorised 
personnel. Only GCP-certified investigators approved by 
the TSG will be given access to the study data set; this 
will include members of the research team involved in 
the data analysis. A unique patient identification number 
(ie, a sequential number starting at K001) will be gener-
ated by the study web-based data entry system for each 
child that is screened by the clinical team. This will be 
used on all paper and electronic data. The electronic 
data management system being utilised for the purpose 
of the study, Qualtrics (http://www. qualtrics. com/), is a 
powerful online system that enables data to be securely 
uploaded and managed from different sites.
All participant data, associated files and hard copy 
questionnaires, including any that might identify partici-
pants, will be accessed only by the research team. Consent 
forms will be stored at Hertfordshire Community NHS 
Trust during the study and will be collected and stored 
at the University of Hertfordshire at the end of the 
study. Patient-identifiable data relating to the study will 
be deleted or destroyed within 6 months of the end of 
the study. Anonymised study data will be archived by the 
University of Hertfordshire for 5 years after study comple-
tion in line with standard research protocols. Investigators 
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will not disclose patient data in any form to anyone not 
involved directly in the study. All electronic data will be 
stored on password-protected computers, and paper files 
will be stored in locked filing cabinets, both of which will 
be kept within locked offices. The video recordings of the 
intervention sessions will be transferred to an encrypted 
external hard drive and deleted from the device. The 
hard drive will be stored in a lockable cabinet in a locked 
office.
eThIcs And dIsseMInATIon
ethical considerations
Ethical approval for this study was granted on 10 November 
2016 by the Cambridge South REC (16/EE/0387). Initial 
Health Research Authority (HRA) approval was granted 
on 18 November 2016. Here, we report version 3.0 of the 
protocol, which received ethical and HRA approval on 15 
March 2017. Any future amendments will be approved by 
the sponsors, HRA and REC as appropriate.
As parents/carers may be likely to be vulnerable to 
coercion around the time of diagnosis, the research 
team will not follow-up for 2 weeks after referral from 
the Hertfordshire Community NHS Trust clinic, at 
which time a researcher will go through the information 
and address any questions before taking consent. The 
participants are minors, so fully informed consent will 
be obtained from their parent/carer. A child-friendly 
written information sheet, a pictorial information sheet 
and a child assent form will also be used as deemed 
appropriate by the parents/carers and the study team. 
The information sheets and consent forms have been 
reviewed by parents of children with ASD and an adult 
with ASD.
The child will be told what is expected of them in the 
intervention sessions. The sessions will be paused or 
stopped if a child shows signs of becoming distressed. 
Their parent/carer will be watching through a one-way 
mirror so they will be able to comfort the child and escort 
them from the room if necessary.
If aftercare is required by a parent/carer or child, then 
appropriate support will be provided by drawing on the 
range of usual therapy, which is available in the NHS 
Trust, for example, play therapy. Where appropriate, 
parents/carers will also be signposted to the National 
Autistic Society for parent support.
To date, studies using Kaspar have not experienced any 
difficulties in children becoming excessively attached to 
the robot. However, if this does occur, then we will follow 
a phased withdrawal protocol after discussion with their 
parents/carers, the therapist and a consultant paediatri-
cian. Depending on clinic room availability and family 
preference, we will provide access to the robot at the 
University of Hertfordshire or Hertfordshire Community 
NHS Trust with a member of the study team. The nature 
of this will vary according to each child, but the principles 
of the phased withdrawal would be to reduce the length 
and frequency of sessions in an appropriate manner, for 
example, by explaining that Kaspar has other children to 
play with.
dissemination plan
The literature regarding the use of social robots in inter-
ventions with children with ASD is currently reliant on 
single case reports; thus, the evidence base requires meth-
odologically robust research designs. Reliable research 
findings will lead to impact beyond the research commu-
nity to practitioners in healthcare and education, and as 
such will facilitate access to wider patient benefit. Our 
dissemination plan has been designed with this in mind 
and was developed in close collaboration with PPI repre-
sentatives.
Our dissemination and impact activities will include 
open-access academic publications in high-impact jour-
nals, presentations at academic and non-academic 
conferences, hosting a free entry public seminar about 
the study and producing briefings for parent groups, 
charities and NHS services. The timing and details for 
these dissemination activities will be discussed at TSG and 
project advisory group meetings.
The research team will write all articles submitted for 
peer-reviewed publications, and authorship inclusion and 
order will be guided by levels of contribution. All publica-
tion material will acknowledge the funding contribution 
from NIHR.
This is a shortened version of the full protocol, which 
is available on request from the corresponding author. 
Requests for access to the anonymised data and statis-
tical code should also be addressed to the corresponding 
author.
dIscussIon
This study will be the first to assess the feasibility of 
conducting an RCT to evaluate a robot-assisted social 
skills intervention for children with ASD. The results of 
this feasibility study will be used to decide whether to 
progress to a full-scale trial, and if so, what methodolog-
ical issues may need to be addressed and changed.
NICE guidelines indicate that children should be 
offered a psychosocial intervention as a first-line treat-
ment, and this should include play-based strategies to 
increase joint attention, engagement and reciprocal 
communication, which Kaspar is designed to do.36 A 
full-scale study will allow the evaluation of the effect of 
the Kaspar intervention soon after diagnosis. Offering 
an early intervention such as Kaspar has the potential to 
improve children’s social skills, to affect their ability to 
access other forms of intervention, for example, speech 
and language therapy, and to improve their long-term 
outcomes.
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